Home
1
Products
2
IR252-897 CD3 antibody3
Home Products Primary antibody IR252-897 CD3 antibody
IR252-897

IR252-897 CD3 antibody

Overview

Product Name

CD3 antibody

Product Number

IR252-897

Gene Description

CD3e molecule, epsilon (CD3-TCR complex)

Clonality

Polyclonal

Host

Rabbit

Species Reactivity

Human

Recommended

Applications Dilutions

Western Blot 1:500 – 1:1000

Immunofluorescence 1:300 – 1:400

Immunohistochemistry (Paraffin) 1:300 – 1:500

Flow Cytometry 1:50 – 1:150

Storage Buffer

100mM Tris Glycine, 20% Glycerol (pH7). 0.025% ProClin 300 was added as a preservative

Concentration

0.69 mg/ml

Purity

Affinity column purified

Storage

Store at +4°C for short term storage. Long time storage is recommended at -20°C

Notes

Gently mix before use. Optimal concentrations and conditions for each application should be determined by the user.

IR252-897 anti-CD3 antibody WB image

IR252-897 anti-CD3 antibody FACS image

8f9bfcd33b805254c21bcd34479c5e76.jpg

bc2aed2c8398e680c534ec9ae9e4a09f.png

All lanes : Anti-CD3 antibody at 1/800 dilution

 

Lysates/proteins at 60 μg per lane

This blot was produced using a 15% SDS-PAGE. Nitrocellulose membrane was then blocked for an hour before being incubated with IR252-897 overnight at 4°C.

ProductCD3 antibody

CatalogIR252-897

Cell : Jurkat

PE labelled secondary antibody.

Unlabelled sample (black) was used as a control.

Data from : National Taiwan Ocean University

IR252-897 anti-CD3 antibody IHC image

IR252-897 anti-CD3 antibody ICC/IF image

43d4c777d756aa484347f7f9057defa3.jpg

701f8481dc96941c70f75fcec967b619.jpg

Immunohistochemical analysis of paraffin embedded Human cancer tissue labeling CD3 with IR252-897 at 1/400.

Immunofluorescence: cells were fixed with 4% paraformaldehyde for 10 min at RT, permeabilized with 0.1% NP-40 for 10 min at RT then blocked with 5% BSA for 30 min at room temperature. Cells were stained with IR252-897 anti- CD3 antibody (red) at 1:300 and 4°C. DAPI (blue) was used as the nuclear counter stain.

1439573
Attachments:
IR252-897_CD3.pdf